Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Oxytocin vs. placebo on response inhibition and face processing in autism  

No medications have been approved by the FDA for the treatment of autism, and no medications have been shown to improve social abilities or language impairments related to the disorder. Basic science and limited clinical research has linked oxytocin deficiency to both repetitive behaviors and social deficits in autism. In this study, functional magnetic resonance imaging (fMRI) scans and social cognition tests will be used to determine the effect of oxytocin in improving social abilities in adults with autism by monitoring improvement in face processing or activation patterns in areas of the brain involved in face processing. The project will also use fMRI to examine the areas of the brain believed to be involved in repetitive behaviors to determine whether oxytocin may be an effective treatment for those symptoms. Project Status


Funder National Institutes of Health
Fiscal Year Funding $1,712.00
Project Number 5M01RR000071-46
Principal Investigator Anagnostou, Athanasius
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LA. Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.
Federal or Private? Federal
Institution Mount Sinai School of Medicine
State/Country New York
Web Link 1 Oxytocin vs. placebo on response inhibition and face processing in autism (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects N/A